317 related articles for article (PubMed ID: 33215790)
1. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
Tada T; Toyoda H; Kumada T; Kurisu A; Sugiyama A; Akita T; Ohisa M; Aikata H; Miki D; Chayama K; Tanaka J
J Viral Hepat; 2021 Mar; 28(3):538-547. PubMed ID: 33215790
[TBL] [Abstract][Full Text] [Related]
2. Long-term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model.
Tada T; Toyoda H; Yasuda S; Kumada T; Kurisu A; Ohisa M; Akita T; Tanaka J
Hepatol Res; 2020 Aug; 50(8):936-946. PubMed ID: 32401388
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort).
Hsu WF; Tsai PC; Chen CY; Tseng KC; Lai HC; Kuo HT; Hung CH; Tung SY; Wang JH; Chen JJ; Lee PL; Chien RN; Lin CY; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Su WW; Chu CH; Chen CJ; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Huang JF; Dai CY; Chuang WL; Yu ML; Peng CY
J Gastroenterol Hepatol; 2021 Oct; 36(10):2884-2892. PubMed ID: 33963615
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication.
Vutien P; Kim NJ; Moon AM; Johnson KM; Berry K; Green PK; Ioannou GN
Aliment Pharmacol Ther; 2024 Feb; 59(3):361-371. PubMed ID: 37955206
[TBL] [Abstract][Full Text] [Related]
5. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL;
Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748
[TBL] [Abstract][Full Text] [Related]
6. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
7. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model.
Tanaka J; Kumada H; Ikeda K; Chayama K; Mizui M; Hino K; Katayama K; Kumagai J; Komiya Y; Miyakawa Y; Yoshizawa H
J Med Virol; 2003 Jul; 70(3):378-86. PubMed ID: 12767000
[TBL] [Abstract][Full Text] [Related]
8. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
[TBL] [Abstract][Full Text] [Related]
9. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
10. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis.
Kumada T; Toyoda H; Yasuda S; Tada T; Ito T; Tanaka J
J Viral Hepat; 2021 Sep; 28(9):1293-1303. PubMed ID: 34185932
[TBL] [Abstract][Full Text] [Related]
12. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
14. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
[TBL] [Abstract][Full Text] [Related]
15. Natural history of hepatitis C virus infection in a large national seroconversion cohort in the direct-acting antiviral agent era: Results from ERCHIVES.
Butt AA; Yan P;
J Viral Hepat; 2021 Jun; 28(6):916-924. PubMed ID: 33763947
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?
Ahumada A; Rayón L; Usón C; Bañares R; Alonso Lopez S
World J Gastroenterol; 2021 Oct; 27(40):6737-6749. PubMed ID: 34790004
[TBL] [Abstract][Full Text] [Related]
17. Chronic Hepatitis C: Advances in Therapy and the Remaining Challenges.
Alqahtani SA; Sulkowski MS
Med Clin North Am; 2023 May; 107(3):423-433. PubMed ID: 37001945
[TBL] [Abstract][Full Text] [Related]
18. Oncologic Implications of Chronic Hepatitis C Virus Infection.
Hwang JP; LoConte NK; Rice JP; Foxhall LE; Sturgis EM; Merrill JK; Torres HA; Bailey HH
J Oncol Pract; 2019 Dec; 15(12):629-637. PubMed ID: 31825756
[TBL] [Abstract][Full Text] [Related]
19. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002
[TBL] [Abstract][Full Text] [Related]
20. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
